Yotta Acquisition Corporation - Right Stock (NASDAQ: YOTAR)

Yotta Acquisition Corporation - Right (NASDAQ:YOTAR) Stock, Quote.Headers.trade-ideas

Yotta Acquisition Corporation - Right

Morgan Stanley analyst Judah Frommer initiates coverage on Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with a Overweight rating and announces Price Target of $35.

News

Price Target

Initiation

Analyst Ratings

BCAX

Morgan Stanley Initiates Coverage On Bicara Therapeutics with Overweight Rating, Announces Price Target of $35

TD Cowen analyst Tyler Van Buren initiates coverage on Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with a Buy rating.

TD Cowen Initiates Coverage On Bicara Therapeutics with Buy Rating

Morgan Stanley analyst Vikram Purohit initiates coverage on Zenas BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Overweight rating and announces Price Target of $40.

ZBIO

Morgan Stanley Initiates Coverage On Zenas BioPharma with Overweight Rating, Announces Price Target of $40

MAIN

Main Street Capital Announces $74.4M Investment To Recapitalize Victory Energy Operations

B of A Securities analyst Julien Dumoulin-Smith maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $343 to $321.

FSLR

B of A Securities Maintains Buy on First Solar, Lowers Price Target to $321

Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) is preparing to launch an AI assistant, powered by OpenAI&#8216;s GPT-4o, aimed at helping drivers transition to electric vehicles. The initiative is part of Uber&#8217;s larger plan to cut down on emissions.
What Happened: The AI assistant was unveiled during Uber&#8217;s Go-Get Zero event in London and is scheduled to debut in the U.S. early next year, with plans for a global rollout. It will provide personalized advice based on the driver&#8217;s location and available incentives. By 2025, the chatbot will expand its capabilities to address questions beyond electric vehicles, Reuters reported on Tuesday.
Uber has pledged $800 million to aid its drivers in transitioning to EVs by 2040. Currently, about 180,000 drivers are making the switch each month in North America and Europe. CEO Dara Khosrowshahi highlighted that Uber drivers are adopting EVs at a rate five times faster than the average motorist in the U.S., Canada, and Europe.
See Also: <a href="https://www.benzinga.com/24/10/41209381/lucid-reports-q3-ev-production-and-delivery-totals-what-to-know?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lucid Reports Q3 EV Production And Delivery Totals: What To Know</a>
In addition, Uber is introducing a mentorship program for EV drivers and offering $50,000 to top merchants on its food delivery platform for sustainability efforts. Pop-up events will allow customers to experience EVs, such as the Lotus Eletre in London and the Rivian R1 in select U.S. cities.
Why It Matters: Uber&#8217;s move to integrate AI into its operations is part of a broader industry trend. In May, Grab Holdings , a competitor in Asia,<a href="https://www.benzinga.com/markets/asia/24/05/39089311/ubers-asia-peer-grab-taps-openai-to-enhance-app-navigation-and-customer-support"> announced a partnership</a> with OpenAI to enhance app navigation and customer support using AI. This highlights the growing importance of AI in improving service delivery and customer experience.
Earlier, in August 2023, Uber had already signaled its intentions to leverage AI with plans for an <a href="https://www.benzinga.com/news/23/08/33512474/uber-joins-ai-bandwagon-with-chatbot-plan-to-level-up-customer-service">AI-powered chatbot</a> to enhance customer service and automate tasks. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41217416/warren-buffett-vs-elon-musk-did-geico-cut-insurance-coverage-on-cybertrucks-for-not-meeting-underwri?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett Vs. Elon Musk: Did Geico Cut Insurance Coverage On Cybertrucks For Not Meeting &#8216;Underwriting Guidelines&#8217;?</a></li>
</ul>
Photo via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Tech

General

UBER

Uber Launches OpenAI's ChatGPT-Based Driver Assistant To Support  Transition To EVs

TD Cowen analyst Vivien Azer downgrades Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) from Buy to Hold and maintains the price target from $68 to $68.

Downgrades

TD Cowen Downgrades Anheuser-Busch InBev to Hold, Maintains Price Target to $68

AEVA

Aeva's 4D LiDAR Chosen As 'Gold Standard' For European OEM's Automated Vehicle Validation Program

Stelco Holdings Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STLC#TSX">STLC</a>) ("Stelco" or the "Company") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act"), in connection with its pending sale to Cleveland-Cliffs Inc. The expiration of the HSR Act waiting period clears an important regulatory hurdle and marks a significant step toward the closing of the sale of Stelco, which is expected to occur in the fourth quarter of 2024 following the satisfaction or waiver of other customary closing conditions and approvals.

TSX:STLC

U.S. Antitrust Review For Cleveland-Cliffs' Acquisition Of Stelco Waiting Period Expires

Baird analyst Joe Vruwink maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Outperform and raises the price target from $175 to $204.

GWRE

Baird Maintains Outperform on Guidewire Software, Raises Price Target to $204

Recent Corporate Developments
<ul>
<li>As previously disclosed, in&nbsp;April 2024&nbsp;Kintara entered into a definitive merger agreement (the &quot;Merger Agreement&quot;) with TuHURA Biosciences, Inc. (&quot;TuHURA&quot;), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara&#39;s wholly-owned subsidiary, whereby Kayak Mergeco will merge with and into TuHURA with TuHURA surviving the merger and becoming Kintara&#39;s direct, wholly-owned subsidiary (the &quot;Merger&quot;). 
	&nbsp;</li>
<li>At Kintara&#39;s special meeting of stockholders held on&nbsp;October 4, 2024, Kintara&#39;s stockholders approved the requisite proposals to effect the completion of the proposed Merger with TuHURA. The proposed Merger is expected to be consummated in&nbsp;mid-October 2024, subject to the satisfaction of the remaining closing conditions under the Merger Agreement. 
	&nbsp;</li>
<li>As of&nbsp;October 7, 2024, four patients have been dosed in Kintara&#39;s open label 15-patient REM-001 study (the &quot;REM-001 Study&quot;) in cutaneous metastatic breast cancer (CMBC). The majority of the costs to run the REM-001 Study will be covered by the&nbsp;$2.0 million&nbsp;Small Business Innovation Research grant Kintara was awarded from the National Institutes of Health.</li>
</ul>

Earnings

Kintara Therapeutics, Inc. - Common Stock

KTRA

Kintara Therapeutics 2024 EPS $(0.32) Up From $(9.27) YoY; Cash And Cash Equivalents $4.9M

Amwell health plan clients can now offer their employer accounts the Hello Heart cardiovascular solution to eligible members and employees with high blood pressure, high cholesterol, or other risk factors for cardiovascular disease. Members can easily access the Hello Heart solution from their current Amwell-powered offering. In addition, members will have access to virtual primary care, urgent care, behavioral health and other clinical program offerings.

Health Care

AMWL

Amwell Announced Hello Heart Is A Partner In The Amwell Clinical Programs Portfolio Available On The Amwell Converge Platform

<ul>
<li>GSK's RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk</li>
<li>Safety and reactogenicity data are consistent with previous results from the phase 3 program</li>
<li>GSK will continue to provide data on longer-term follow-up to help recommending bodies determine future revaccination schedules</li>
</ul>

Biotech

Large Cap

GSK Announced New Data From The AReSVi-006 Phase 3 Trial Of A Single Dose Of Arexvy Respiratory Syncytial Virus Vaccine In Adults Aged 60 Years And Older

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into an AI and ML research collaboration with X-Chem, Inc. (X-Chem), a leader in small molecule drug discovery, to accelerate development of Tonix's oral broad-spectrum antivirals.
Tonix's TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) for up to $34 million to advance the development of Tonix's TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug (IND) submission and a first-in-human Phase 1 clinical study.
"We are excited to enter into this research collaboration with X-Chem, which we believe will expand our capabilities, and deepen our understanding of host-targeted small molecule therapeutics for a variety of targets," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "With the support of X-Chem's drug discovery AI/ML technology, we expect to optimize the physicochemical properties, pharmacokinetics, and safety attributes of our drug candidates."
"We are excited to partner with Tonix in their pursuit of such important programs in human health, at the intersection of laboratory and in silico technology. This collaboration highlights how integrative work continues to leverage the creation of target-specific high-quality data to drive AI drug discovery," said Erin Davis, Ph.D., Chief Technology Officer of X-Chem."
The DTRA contract awarded to Tonix is expected to help fund and accelerate the development of the Company's lead oral host-directed TNX-4200 broad-spectrum antiviral program. The TNX-4200 program aims to reduce viral load and to allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Tonix plans to leverage previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention of biothreat agents.
For the oral broad-spectrum antiviral programs, including TNX-4200, Tonix is utilizing its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house. The RDC is located in Maryland's ‘I-270 biotech corridor' and is close to the center of the U.S. biodefense research community.

Government

Regulations

TNXP

Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates with X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML

Wall Street is gearing up for a firmer start on Tuesday after <a href="https://www.benzinga.com/news/earnings/24/10/41221716/dow-dips-around-400-points-as-treasury-yields-top-4-investor-optimism-declines-but-fear-index-remai">stocks pulled back sharply in the previous session. </a>The index futures firmed up amid a pullback in the 10-year Treasury note yield and dovish comments issued by a Federal Reserve official. Speaking at a European Central Bank event in Frankfurt, Germany, Fed Governor Adriana Kugler said if the <a href="https://www.benzinga.com/government/24/10/41224292/feds-adriana-kugler-will-support-for-more-rate-cuts-if-inflation-declines">progress seen on the inflation</a> front continues, she would support additional cuts in the Fed fund rate. She also reiterated the recent Fed rhetoric that the central bank&#8217;s attention has shifted away from inflation toward maximum employment.
With China refraining from issuing details on further stimulus, sentiment soured in Asia. This also weighed down on oil prices. Traders may focus on the bond yields and a Fed speech scheduled during market hours. The offsetting impact could come from the negative reaction to PepsiCo, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) earnings which could intensify anxiety concerning the third-quarter reporting season. Some key first-tier data due for the remainder of the week could introduce some caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.37%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.46%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.13%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.01%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.30% to $569.53 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) moved 0.31% higher to $483.59, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
Stocks fell sharply on Monday, reversing course from the jobs data-induced upside seen last Friday. The major indices opened lower and moved roughly sideways below the unchanged line before they fell sharply in the afternoon, as traders weighed in on the rise in bond yields, the imminent reporting season., some negative tech tidings and a couple of Fed speeches. The indices consolidated around the lower levels in the last hour of trading before closing notably lower.
Hurricane Milton, the newest one of the 2024 hurricane season, also exerted downward pressure on insurance stocks.
All but one of the S&amp;P 500 sector classes closed in the red, with energy stocks bucking the downtrend. Utilities and communication services stocks fell sharply, while consumer discretionary and consumer staple stocks as well as rate-sensitive financial stocks came under selling pressure. 
The S&amp;P 500 settled at a two-week low and the 30-stock Dow Industrials Average closed at the lowest since Sept. 25. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.18%</td>
<td>17,923.90</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.96%</td>
<td>5,695.94</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>-0.94%</td>
<td>41,954.24</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.89%</td>
<td>2,193.09</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
In the wake of stronger-than-expected non-farm payrolls gains for September and a downtick in the unemployment rate, Morgan Stanley&#8217;s Chief U.S. Market Strategist Mike Wilson said the firm is taking profit on its long-standing large-cap overweight stocks and moving to neutral on large versus small caps.
A rate-cutting cycle in and of itself does not justify small cap outperformance but &#8220;an outsized start to a rate-cutting cycle combined with a much stronger than expected payroll print does make the risk-reward for a large cap overweight less attractive, at least tactically,&#8221; he said.
&#8220;Improving small business sentiment and a rising ISM PMI are also supportive of the idea that small caps can keep up with large caps for the time being,&#8221; Wilson said. Within small caps, he recommended staying up the quality curve, ie companies with stronger margin and balance sheet profiles.
Meanwhile, Wisdom Tree Senior Economist and Wharton professor Jeremy Siegel sees the backdrop remain &#8220;quite positive&#8221; for stocks. The climb in the bond yield reflects investor expectations that a recession is unlikely. &#8220;This lower probability of a recession is also good for equities, particularly the lower valued segments of the market like small caps which are very sensitive to recession fears,&#8221; the economist said.
Siegel expects the S&amp;P 500 to hit 6,000 by the end of 2024 but the returns in 2025 to be more subdued than in 2023 and 2024.
Economists do not expect oil to rise exorbitantly due to the Middle East tensions as the U.S. has achieved greater energy self-sufficiency over the last few decades.
&#8220;Overall, the backdrop remains quite positive for equities,&#8221; Siegel said, adding that &#8220;the Fed is on course for cutting five to six times by next summer, while the economy remains quite resilient.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data:
<ul>
<li>The Commerce Department is due to release the trade deficit report for August at 8:30 a.m. EDT, with economists, on average, expecting a deficit of $70.8 billion for August compared to the previous month&#8217;s deficit of $78.8 billion.</li>
<li>The Atlanta Fed GDPNow report for the third quarter is due at 10:30 p.m. EDT.</li>
<li>Among the Fed speakers scheduled for the day are:
<ul>
<li>Atlanta Fed President Raphael Bostic: 12:45 p.m. EDT</li>
<li>Boston Fed President Susan Collins: 4 p.m. EDT</li>
<li>Federal Reserve Vice Chair Philip Jefferson: 7:30 p.m. EDT</li>
</ul>
</li>
<li>The Treasury is set to auction three-year notes at 1 p.m. EDT.</li>
</ul>
Stocks In Focus:
<ul>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) and Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) moved down over 6% each <a href="https://benzinga.grsm.io/register174">in premarket trading.</a></li>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) climbed over 1.71%, extending the gains from Monday.</li>
<li>PepsiCo slipped over 1% after the company&#8217;s third-quarter revenue missed expectations and it reduced its 2024 organic growth outlook.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
The WTI-grade crude oil futures fell over 2% following an extended rally seen in the wake of the Middle East tensions and gold futures moved modestly lower. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slipped a percent over the past 24 hours, with the apex crypto trading below $62.5K.
The 10-year Treasury note edged down marginally to 4.022%.
The Asian markets closed on a mixed note as traders reacted negatively to Wall Street&#8217;s pullback overnight. While Hong Kong and the Japanese markets led the decliners, the Chinese market, which reopened after the weeklong National Day holiday, extended its winning run. The Shanghai Composite Index ended up 4.59%, although well off the day&#8217;s high, after the chairman of China&#8217;s economic planner, Zheng Shanjie did not provide any further clarity on fresh fiscal stimulus. Hong Kong&#8217;s Hang Seng Index tumbled 9.41%.
European stocks also fell in early trading, with the U.K.&#8217;s FTSE 100 Index underperforming as the yield on 10-year U.K. government gilts rose to 4.2%, its highest level since the general election in July.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41222716/as-florida-prepares-for-one-of-deadliest-hurricanes-here-are-some-potential-stock-winners-and-lo">As Florida Prepares For One Of Deadliest Hurricanes, Here Are Some Potential Stock Winners And Losers From Milton Threat</a></li>
</ul>
Image Via Pixabay

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

NVDA

WYNN

US Stocks Poised To Bounce Back As Bond Yields Dip, Oil Prices Slide, PepsiCo Pulls Back: Set-up 'Quite Positive' For Equities, Says Economist

IAS Provides Advertisers End-to-End Coverage Across TikTok&#39;s New Placements Including Profile,&nbsp;Search, Following Feeds, and TikTok Lite

IAS Expands TikTok Media Quality Coverage To 75+ New Markets, Testing Video Exclusion List For Advertisers

Management

Opthea Appoints Parisa Zamiri And Tom Reilly Respectively As Chief Medical Officer And Chief Financial Officer, As The Company Continues To Prepare For The Sozinibercept Phase 3 Topline Data Readouts Of COAST Anticipated In Early Q2 Calendar Year 2025 And ShORe In Mid Calendar Year 2025

Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable&nbsp;aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing &nbsp;CRISPR technology for crustaceans, following a successful first year.
&nbsp;
The collaboration aims to provide a sustainable solution to existing limitations in gene editing for non-model organisms with sparse genomic data and protocols, focusing on improving key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans, targeting giant freshwater prawn, white leg shrimp and red swamp crayfish.
The global shrimp market size was USD 40.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.09% during the 2024-2032 period[1]. The global crayfish market is projected to grow at a CAGR of 31.5% between 2024 and 2032[2]. These growing markets increasingly emphasize the need to expand sustainable aquaculture, making the technology developed in the frame of the collaboration exceptionally relevant.
During the first year the partners successfully met the collaboration's planned goals. Evogene leveraged its advanced&nbsp;GeneRator AI&nbsp;tech-engine and provided predictions for optimal guide RNAs (gRNAs), through several novel features: utilization of un-annotated genomes (lacking gene models), consideration of natural DNA variance in gRNAs design, and off-target prediction to increase editing specificity. This allowed Watershed and BGU to successfully produce the first edited giant freshwater prawn&nbsp;(Macrobrachium rosenbergii) with a selected target trait of colored eye, post larvae at advanced life stages, thereby achieving the main milestone in the utilization of CRISPR technology in crustaceans.
In the second year, the collaboration's main target is to industrially scale-up CRISPR technology for giant freshwater prawn&nbsp;and expand the obtained application to the additional crustacean species, white leg shrimp (Litopenaeus vannamei) and red swamp crayfish (Procambarus clarkia). &nbsp;

EVGN

Watershed and Evogene Receive Grant to Advance CRISPR Tech for Crustaceans, Targeting Sustainable Aquaculture

TD Cowen analyst Robert Moskow downgrades Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Buy to Hold and lowers the price target from $300 to $270.

TD Cowen Downgrades Constellation Brands to Hold, Lowers Price Target to $270

GILT

Gilat Satellite Networks Secures ~$4M Contract To Deliver Connectivity Services To Rural Regions In Latin America

Press Releases

Yotta Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

Yotta Acquisition Corporation Announces Entering into a Merger Agreement with DRIVEiT Financial Auto Group, Inc., an Operator of Electric Vehicle Superstores

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Yotta Acquisition Corporation - Right

Yotta Acquisition Corporation - Right (YOTAR) Forecast

Yotta Acquisition Corporation - Right (NASDAQ:YOTAR) Stock, Quote.Headers.trade-ideas